These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 14986701)

  • 1. Data protection: an anti-generic weapon.
    Prescrire Int; 2003 Dec; 12(68):235. PubMed ID: 14986701
    [No Abstract]   [Full Text] [Related]  

  • 2. [European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
    Alván G
    Lakartidningen; 2003 Oct; 100(44):3541-2. PubMed ID: 14651017
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 4. [Marketing of pediatric drugs].
    Pabst JY
    Soins Pediatr Pueric; 2003; (210):18-9. PubMed ID: 12683130
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of new drugs and indications in 2002: financial speculation or better patent care?
    Prescrire Int; 2003 Apr; 12(64):74-7. PubMed ID: 12674131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMEA tackles "generic" biologic drug issues.
    Rice M
    J Natl Cancer Inst; 2006 Apr; 98(7):435-6. PubMed ID: 16595776
    [No Abstract]   [Full Text] [Related]  

  • 7. Fractured European market undermines biosimilar launches.
    Moran N
    Nat Biotechnol; 2008 Jan; 26(1):5-6. PubMed ID: 18183000
    [No Abstract]   [Full Text] [Related]  

  • 8. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T
    Eur J Cancer; 2006 Mar; 42(4):446-55. PubMed ID: 16129598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outsourcing clinical trials.
    Nicholas J
    J Natl Cancer Inst; 2012 Jul; 104(14):1043-5. PubMed ID: 22781429
    [No Abstract]   [Full Text] [Related]  

  • 10. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 12. Something is moving in European drug research for children, but a more focused effort concerning all therapeutic needs is necessary.
    Pandolfini C; Bonati M
    Arch Dis Child; 2008 Aug; 93(8):715. PubMed ID: 18644943
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of the European Clinical Trials Directive on published drug research in anaesthesia.
    Walker E; Hankins MC; White SM
    Anaesthesia; 2009 Sep; 64(9):984-9. PubMed ID: 19686484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How similar do 'biosimilars' need to be?
    Schellekens H
    Nat Biotechnol; 2004 Nov; 22(11):1357-9. PubMed ID: 15529154
    [No Abstract]   [Full Text] [Related]  

  • 16. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 17. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
    Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
    Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
    [No Abstract]   [Full Text] [Related]  

  • 18. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 19. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 20. The end of the beginning?
    Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.